hyperCVAD

Hyper-CVAD is an intensive multi-agent chemotherapy regimen used to treat certain malignant hematologic neoplasms, most notably adult acute lymphoblastic leukemia (ALL) and lymphoblastic/ high-grade lymphomas such as lymphoblastic lymphoma and some non-Hodgkin lymphomas. The regimen alternates between two courses, referred to as Course A and Course B, typically given in 21- to 28-day cycles for a total of several cycles depending on disease and response. Course A consists of cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone. Course B comprises high-dose methotrexate with leucovorin rescue and cytarabine. In some regimens rituximab is added (R-hyper-CVAD) for CD20-positive B-cell neoplasms.

Treatment is intensive and usually delivered in a hospital setting with close monitoring. Before and during methotrexate-containing cycles, patients receive leucovorin rescue and aggressive hydration and monitoring of renal function to limit toxicity. Supportive care includes antiemetics, infection prophylaxis, management of tumor lysis syndrome, and growth factor support as needed.

Efficacy varies by disease and patient factors but hyper-CVAD has been associated with high complete remission rates in adult ALL and lymphoblastic lymphoma, especially in younger, fit patients. Toxicities include myelosuppression, mucositis, neurotoxicity, hepatotoxicity, nephrotoxicity, infections, and endocrinologic effects; long-term risks may include secondary malignancies and fertility effects. The regimen requires specialized medical oversight and is typically considered after careful assessment of risks and potential benefits.